NCT05000892View on ClinicalTrials.gov

Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Untreated Salivary Gland Malignant Neoplasms

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 10, 2021

Primary Completion Date

June 1, 2023

Study Completion Date

October 1, 2027

Conditions

Salivary Gland Malignant NeoplasmsSalivary Gland Tumors

Interventions

DRUG

Sintilimab , Carboplatin, Nab-paclitaxel

Patients receive Sintilimab IV on day 1, paclitaxel IV on day 1 and carboplatin IV on day 1 . Treatment repeats every 21 days for up to 3 cycles in the absence of disease progression or unacceptable toxicity.

Trial Locations (1)

510000

RECRUITING

Sun Yat-sen Memorial Hospital, Guangzhou

All Listed Sponsors

lead

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER